A regulatory decision is expected during the first quarter of 2025. The Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

3.10 The company submitted a partitioned survival model to estimate the cost effectiveness of trastuzumab deruxtecan compared with trastuzumab emtansine. It has 3 health states: progression-free ...

Among these developments is trastuzumab deruxtecan (brand name: Enhertu), which offers new hope specifically for patients who harbor HER2 mutations in their lung cancer, a type once challenging to ...

To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload ...

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 ...

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

The safety profile of the novel antibody-drug conjugate was "manageable" and comparable to that of a similar drug, trastuzumab deruxtecan, researchers said. If approved, trastuzumab rezetecan ...

Second-line trastuzumab deruxtecan-nxki significantly improved outcomes for advanced gastric cancers compared with paclitaxel plus ramucirumab. Confirmation of HER2 status after first-line ...

Breast Cancer Now said the approval of cancer treatment Trastuzumab deruxtecan ushered an “exciting new era” of treatment. It is among four different cancer treatments approved for use by NHS ...

Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated ...

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.

Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant and clinically ...